malignancy
Conditions
Interventions
Immune checkpoint inhibitors treatment group:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
No minimum to 200 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with malignant tumors by pathology, including solid tumors and hematological tumors; (2) Have used ICIs at least once; (3) The clinical medical records are complete and reliable, with complete efficacy evaluation results, adverse reaction records, and survival follow-up data.
Exclusion criteria
Exclusion criteria: Patients with incomplete clinical data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of serious adverse events;Postoperative complication rate;hospitalization days after operation;survival time;Baseline data of patients; | — |
Countries
China
Contacts
Public ContactJinhan he
Department of Pharmacy, West China Hospital, Sichuan University
Outcome results
None listed